INTERNATIONAL SOCIETY FOR PHARMACEUTICAL ENGINEERING INC (EIN 592009272) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1980

Legal Domicile

Principal Officer

MARK HERNICK

Phone

8139602105

Tax Period

2024-01-01 to 2024-12-31

INTERNATIONAL SOCIETY FOR PHARMACEUTICAL ENGINEERING INC, founded in 1980, is a mid-sized nonprofit that reported $17.3M in total revenue in fiscal year 2024. Revenue decreased 6% compared to the prior year.

Mission

TO LEAD SCIENTIFIC, TECHNICAL AND REGULATORY ADVANCEMENT THROUGHOUT THE ENTIRE PHARMACEUTICAL LIFECYCLE.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $16,417,024

Investment Income $285,220

Other Revenue $602,599

TOTAL REVENUE $17,304,843

Expense Breakdown

Grants Paid $0

Salaries & Benefits $7,490,434

Fundraising Expenses $0

Other Expenses $10,303,080

TOTAL EXPENSES $17,793,514

Year-over-Year Comparison

	2024	2023	Change
Revenue	$17,304,843	$18,333,665	-0.1%
Expenses	$17,793,514	$17,091,709	+0.0%
Net Income	$-488,671	$1,241,956	-1.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

750

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$814,078

Total Directors

Key Employees

$201,798

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
THOMAS HARTMAN	PRESIDENT & CEO (OUTGOING 2024)	40.00	Officer	$375,183	$22,038	$397,221
MARK HERNICK	CHIEF FINANCIAL & OPERATING OFFICER	40.00	Officer	$289,654	$27,203	$316,857
JESSICA BLEESS	VP, CONFERENCES & DIGITAL ENGAGEMENT	40.00	Key Emp	$189,489	$12,309	$201,798
CLIFTON DUNHAM	SR. DIRECTOR, BUSINESS DEVELOPMENT	40.00	Highest	$188,579	$11,983	$200,562
PHILIP LIPNICK	DIRECTOR, INFORMATION TECHNOLOGY	40.00	Highest	$165,318	$18,276	$183,594
TORI JOHNSON	DIRECTOR, DEVELOPMENT & FOUNDATION OPERATIONS	0.00	Highest	$159,306	$20,307	$179,613
JESSICA HARDY	SR. DIRECTOR, MEMBERSHIP & CHAPTER RELATIONS	40.00	Highest	$148,462	$25,761	$174,223
ROCHELLE MAY	SR. DIRECTOR, PUBLICATIONS	40.00	Highest	$142,117	$25,219	$167,336
MICHAEL RUTHERFORD	INTERIM CEO	40.00	Officer	$100,000	$0	$100,000
JEFF BISKUP PE	CHAIR	1.00	Officer Director	$0	$0	$0
SCOTT BILLMAN	IMMEDIATE PAST CHAIR	1.00	Officer Director	$0	$0	$0
VIVIANNE ARENCIBIA	VICE CHAIR	1.00	Officer Director	$0	$0	$0
MICHAEL MARTIN	SECRETARY	1.00	Officer Director	$0	$0	$0
YLVA EK	TREASURER	1.00	Officer Director	$0	$0	$0
NINA CAUCHON PHD	DIRECTOR (OUTGOING 2024)	1.00	Director	$0	$0	$0
DAVID CHURCHWARD	DIRECTOR	1.00	Director	$0	$0	$0
LIZ DOOLEY MSC	DIRECTOR	1.00	Director	$0	$0	$0
NORMAN GOLDSCHMIDT	DIRECTOR	1.00	Director	$0	$0	$0
JAMES GRUNWALD	DIRECTOR (INCOMING 2024)	1.00	Director	$0	$0	$0
SHANSHAN LIU	DIRECTOR (INCOMING 2024)	1.00	Director	$0	$0	$0
SARAH MIKSINSKI	DIRECTOR	1.00	Director	$0	$0	$0
TERESA MINERO	DIRECTOR (OUTGOING 2024)	1.00	Director	$0	$0	$0
VIVIEN SANTILLAN	DIRECTOR (INCOMING 2024)	1.00	Director	$0	$0	$0
GEORG SINGEWALD PHD	DIRECTOR	1.00	Director	$0	$0	$0
HIROFUMI SUZUKI	DIRECTOR (OUTGOING 2024)	1.00	Director	$0	$0	$0
TIM WATSON PHD	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$17,304,843	$17,793,514	$16,930,698	$-488,671
2023	$18,333,665	$17,091,709	$17,990,571	$1,241,956
2022	$15,080,135	$13,532,053	$16,259,417	$1,548,082
2021	$10,779,198	$10,756,916	$11,781,437	$22,282
2020	$9,646,395	$9,893,705	$10,682,582	$-247,310
2019	$14,236,345	$13,558,113	$12,426,015	$678,232
2018	$12,739,970	$12,604,240	$10,235,966	$135,730

INTERNATIONAL SOCIETY FOR PHARMACEUTICAL ENGINEERING INC